主 办:北 京 中 医 药 大 学
ISSN 2095-6606 CN 10-1157/R

现代中医临床 ›› 2021, Vol. 28 ›› Issue (2): 40-46.doi: 10.3969/j.issn.2095-6606.2021.02.009

• 文献研究 • 上一篇    下一篇

中医药治疗代谢综合征的系统评价再评价*

崔丽军, 曹卉娟, 于河#, 李勋欣, 刘铁钢, 白辰, 谷晓红   

  1. 北京中医药大学中医学院 北京 100029
  • 收稿日期:2020-08-03 出版日期:2021-03-30 发布日期:2021-03-30
  • 通讯作者: #于河,女,博士,教授,硕士生导师,E-mail:yuhe221@126.com
  • 作者简介:崔丽军,女,在读硕士生
  • 基金资助:
    *国家自然科学基金青年基金项目(No.81704121),北京中医药大学师承博士后项目(No.1000062620141)

Traditional Chinese medicine treatment for metabolic syndrome: An overview of systematic reviews*

Cui Lijun, Cao Huijuan, Yu He#, Li Xunxin, Liu Tiegang, Bai Chen, Gu Xiaohong   

  1. School of Chinese Medicine, Beijing University of Chinese Medicine, Beijing 100029
  • Received:2020-08-03 Online:2021-03-30 Published:2021-03-30

摘要: 目的 评价中医药干预代谢综合征系统评价的方法学质量及其结局指标的可靠程度。方法 电子检索Cochrane Library、Pubmed、Web of Science,中国知网、维普、万方、中国生物医学文献数据库有关中医药治疗代谢综合征的系统评价,筛选出符合纳入标准的系统评价,检索时间为建库日至2020年3月。采用AMSTAR 2量表评价纳入研究的方法学质量,运用GRADE系统对纳入研究的结局指标进行证据质量分级。结果 共纳入17个系统评价,其中进行meta分析15篇。AMSTAR 2评分均为极低质量。GRADE分级结果显示,2个结局指标的证据质量为高,8个结局指标的证据质量为中,19个结局指标的证据质量为低,60个结局指标的证据质量为极低。结论 按现行评价标准显示关于代谢综合征治疗的系统评价整体方法学质量较低,结局指标可靠程度受影响,因此,临床在参考系统评价的结论时需结合临床实际情况全面考虑适用性,期待未来开展高质量的研究,为代谢综合征的临床治疗提供指导。

关键词: 中医药, 代谢综合征, 系统评价再评价, AMSTAR 2量表, GRADE系统

Abstract: Objective To evaluate the quality of methodology and the reliability of its outcome indicators in systematic reviews of traditional Chinese medicine in the treatment of metabolic syndrome. Methods A few English and Chinese electronic databases including PubMed,CochraneLibrary, Web of Science, CNKI, VIP,CBM and Wanfang were retrieved electronically to screen out the systematic reviews of traditional Chinese medicine treatment for metabolic syndrome from inception to March 2020 that met the inclusion criteria. The method ological quality of the included systematic reviews was evaluated by using the AMSTAR 2 tool,and the quality of the outcome indicators of the included systematic reviews was further graded according to the GRADE system. Results A total of 17 systematic reviews were included, including 15 meta-analyses. The AMSTAR2 evaluation showed that all systematic evaluation was very low. The findings of GRADE evaluation showed that there were 2 high quality indicators,8 intermediate quality indicators,19 low-level quality indicators and 60 extremely low-level quality indicators. Conclusions The available evidence shows that the overall methodological quality of the systematic reviews for the treatment of metabolic syndrome is low, and the reliability of the outcome indicators is low. Therefore, the clinical should be cautious in using the conclusions of the systematic reviews, and high-quality research needs to be carried out in futurein order to obtain high-quality clinical evidence and provide guidelines for the treatment and management of metabolic syndrome.

Key words: traditional Chinese medicine, metabolic syndrome, overview of systematic reviews, AMSTAR 2 scale, GRADE system

中图分类号: 

  • R259